Optimizing Intensive Chemotherapy Management in Secondary AML Through Academic Community Collaboration - Episode 6
Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML
Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.
Video Player is loading.
Video content above is prompted by the following:
- Please discuss the NCCN guideline recommended first-line treatment options for patients with newly diagnosed high-risk or secondary AML who are potential candidates for intensive chemotherapy induction.
- Please briefly review the study design & efficacy study of CPX-351 vs. 7+3.
- How do you monitor and manage potential adverse effects in these patients?
- Describe management of both 7+3 and CPX-351.
- How does your approach differ between the two regimens?
Related Content:
